Key Highlights

● Ryoncil Revenue rose to $28 million, a strong jump from the prior period.

● Mesoblast's American depositary shares climbed to $15.63 among the Nasdaq Composite's biggest gainers.

● Mesoblast finished a Phase 3 back pain trial and held positive FDA talks.

● Cash stood at about $99 million as the company prepares a regulatory submission.

Mesoblast (NASDAQ:MESO) shares soared on Thursday after the regenerative-medicine company reported strong growth in sales of its approved therapy Ryoncil and progress toward a new regulatory filing.

Ryoncil takes center stage

Mesoblast gave investors two reasons to cheer on Thursday, October 29: a product that is selling, and a pipeline that is moving.

Revenue from Ryoncil, the company's approved cell therapy, rose to $28 million, according to one report, a strong jump from the prior period. That growth pushed the stock sharply higher, with the American depositary shares climbing to $15.63, the report said, among the biggest gainers on the Nasdaq Composite.

Ryoncil is used to treat steroid-refractory acute graft-versus-host disease in children, a serious complication that can follow bone marrow transplants when donor immune cells attack the patient's body. For a company that spent years working toward approval, steadily rising sales suggest the therapy is gaining traction.

The pipeline catalyst

Mesoblast also reported progress beyond Ryoncil. The company has finished a Phase 3 trial in chronic low back pain and has held positive discussions with the U.S. Food and Drug Administration about a planned filing, according to the same report.

Chronic low back pain is a far larger market than pediatric graft-versus-host disease. A therapy that reaches approval there could transform the company's revenue prospects, which is why progress toward a filing draws so much attention.

The company's cash stood at about $99 million, the report said. For a biotech preparing for a regulatory submission while building commercial sales, the cash position is an important gauge of how much runway it has.

Health care carried the tape

Mesoblast's rally came on a banner day for health care. The sector was the best performer in the S&P 500, led by Eli Lilly (NYSE:LLY), which jumped after raising its revenue guidance, and Merck (NYSE:MRK), which beat estimates and lifted its outlook. Glaukos (NYSE:GKOS) and Teladoc (NYSE:TDOC) also surged on strong results, according to the same report.

Investors rotated into health care, financials and real estate as they sold mega-cap technology, a shift that helped soften the blow to the broader indexes.

The Nasdaq Composite still tumbled 365.13 points to 26,184.72 as Alphabet (NASDAQ:GOOGL) suffered its worst day since its 2004 IPO. The S&P 500 slipped 23.59 points to 7,720.39, while the small-cap Russell 2000 climbed 28.71 points to 2,859.22.

"Money is rotating within the market rather than leaving it," said one market strategist, according to market commentary.

Rates and risk appetite

The day's economic data delivered mixed signals. Third-quarter GDP grew faster than expected, accelerating from the second quarter, but September PCE Inflation ran hot. Those numbers kept the Federal Reserve's next move in focus after it held rates steady on Wednesday. Two officials dissented in favor of a hike, and futures markets leaned toward an increase in December.

For development-stage and early-commercial biotechs, rates matter because higher borrowing costs make funding more expensive. Treasury yields eased on Thursday, slipping back from multi-decade highs, which offered some relief to rate-sensitive corners of the market.

What to watch

The next milestone for Mesoblast is the planned FDA filing in chronic low back pain. Investors will look for a timeline and for details on what the agency's positive discussions mean for the submission.

Ryoncil's sales trajectory also bears watching. Continued growth would strengthen the company's financial position as it prepares for a potentially larger launch, while the cash balance will be tracked closely against spending needs.

On the broader front, Friday's Employment Cost index and the Fed's December 8–9 meeting will shape the rate environment that influences biotech valuations.